GLP-1 medications are among the most prescribed and most debated drugs in the country. Nearly everyone asks the same question: will my insurance pay for it? In 2026 the answer is changing. It is also specific, conditional, and easy to get wrong.

One clarification first, because it trips up many coverage questions. Ozempic and Mounjaro are approved to treat type 2 diabetes. Wegovy and Zepbound are the same underlying medicines approved for weight loss. Insurance plans often cover the diabetes versions while excluding the weight-loss ones, so the exact drug and the exact reason it is prescribed both matter.

Medicare: a temporary program starting July 2026

For years, Medicare did not cover drugs used only for weight loss. That changes, partially and temporarily, with a new program called the Medicare GLP-1 Bridge. Beginning July 1, 2026, eligible Medicare Part D beneficiaries can get certain GLP-1 medications used to reduce excess body weight for a flat 50 dollar monthly copay. According to CMS, the eligible products are Wegovy, Zepbound, and Foundayo when used for weight reduction.

This is a demonstration, not a permanent benefit. It runs from July 1, 2026 through December 31, 2027, and CMS uses a single central processor to handle prior authorization, claims, and payment to pharmacies. Because the program runs outside the normal Part D benefit flow, those 50 dollar copays do not count toward your annual Part D out-of-pocket cap.

Who qualifies

Eligibility runs through the program's clinical criteria, which include a body mass index threshold (reported at 35 or higher on its own, or 27 or higher combined with other clinical factors). Because this is a clinical determination, the number on a chart is where the process starts, not where it ends. Your prescriber and the program's central approval system make the call. CMS publishes the specifics on its information for Medicare beneficiaries page.

Medicaid: state by state, and changing

Medicaid works differently. Coverage of GLP-1s for weight management has long been optional for states, and that patchwork is changing. A separate, longer-term CMS effort, the BALANCE Model, is set to begin in Medicaid as early as May 2026 and in Medicare Part D in January 2027. In practice, your Medicaid coverage still depends heavily on which state you live in, and this year's answer may differ from last year's.

Private insurance: still the wild card

If you have coverage through an employer or the marketplace, there is no single rule. Some plans cover GLP-1s for obesity. Some cover them only for diabetes. Some exclude weight-loss use entirely. Many that do cover them require prior authorization and proof that you have tried other approaches first.

How to actually confirm your coverage

  • Find the drug by name on your plan's formulary, the list of covered medications. Coverage for diabetes and coverage for weight loss are often listed separately.
  • Ask specifically about prior authorization and step therapy. A drug can be covered and still require paperwork before the plan pays anything.
  • Get the answer in writing. A coverage promise made over the phone is only worth as much as your ability to prove the call happened.
  • For Medicare, confirm whether your specific Part D or Advantage plan is taking part in the demonstration, and what its approval process looks like.

The broader trend is real: coverage is expanding after years of near-total exclusion. But expanding is not the same as automatic. What separates the two is a formulary lookup and a prior-authorization form, and both are worth your time before you build a budget around a prescription.

Sources

Naomi Foster writes about healthcare coverage and costs for Encore Editorial. This piece summarizes program details reported as of mid-2026; verify the specifics against your own plan and official Medicare or Medicaid sources before making decisions. Corrections go through our contact page.